ARVN Quote, Financials, Valuation and Earnings

Hepion Pharmaceuticals has a net margin of -76.18% compared to Arvinas's net margin of --. Arvinas's return on equity of -32.96% beat Hepion Pharmaceuticals's return on equity of --.

Arvinas has a consensus price target of $41.74, signalling upside risk potential of 536.23%. On the other hand Hepion Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 325916.08%. Given that Hepion Pharmaceuticals has higher upside potential than Arvinas, analysts believe Hepion Pharmaceuticals is more attractive than Arvinas.

Arvinas has a beta of 2.305, which suggesting that the stock is 130.541% more volatile than S&P 500. In comparison Hepion Pharmaceuticals has a beta of 1.794, suggesting its more volatile than the S&P 500 by 79.389%.

Arvinas has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Hepion Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arvinas pays -- of its earnings as a dividend. Hepion Pharmaceuticals pays out -- of its earnings as a dividend.

Arvinas quarterly revenues are $59.2M, which are larger than Hepion Pharmaceuticals quarterly revenues of --. Arvinas's net income of -$45.1M is lower than Hepion Pharmaceuticals's net income of -$4.9M. Notably, Arvinas's price-to-earnings ratio is -- while Hepion Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arvinas is 1.79x versus -- for Hepion Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of -76.18% compared to Arvinas's net margin of 2.31%. Arvinas's return on equity of -32.96% beat Pfizer's return on equity of 8.91%.

Arvinas has a consensus price target of $41.74, signalling upside risk potential of 536.23%. On the other hand Pfizer has an analysts' consensus of $31.26 which suggests that it could grow by 36.08%. Given that Arvinas has higher upside potential than Pfizer, analysts believe Arvinas is more attractive than Pfizer.

Arvinas has a beta of 2.305, which suggesting that the stock is 130.541% more volatile than S&P 500. In comparison Pfizer has a beta of 0.670, suggesting its less volatile than the S&P 500 by 32.954%.

Arvinas has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 7.36% to investors and pays a quarterly dividend of $0.43 per share. Arvinas pays -- of its earnings as a dividend. Pfizer pays out 118.44% of its earnings as a dividend.

Arvinas quarterly revenues are $59.2M, which are smaller than Pfizer quarterly revenues of $17.8B. Arvinas's net income of -$45.1M is lower than Pfizer's net income of $410M. Notably, Arvinas's price-to-earnings ratio is -- while Pfizer's PE ratio is 16.29x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arvinas is 1.79x versus 2.06x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

Stoke Therapeutics has a net margin of -76.18% compared to Arvinas's net margin of -46.35%. Arvinas's return on equity of -32.96% beat Stoke Therapeutics's return on equity of -44.32%.

Arvinas has a consensus price target of $41.74, signalling upside risk potential of 536.23%. On the other hand Stoke Therapeutics has an analysts' consensus of $23.88 which suggests that it could grow by 301.94%. Given that Arvinas has higher upside potential than Stoke Therapeutics, analysts believe Arvinas is more attractive than Stoke Therapeutics.

Arvinas has a beta of 2.305, which suggesting that the stock is 130.541% more volatile than S&P 500. In comparison Stoke Therapeutics has a beta of 1.089, suggesting its more volatile than the S&P 500 by 8.901%.

Arvinas has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stoke Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arvinas pays -- of its earnings as a dividend. Stoke Therapeutics pays out -- of its earnings as a dividend.

Arvinas quarterly revenues are $59.2M, which are larger than Stoke Therapeutics quarterly revenues of $22.6M. Arvinas's net income of -$45.1M is lower than Stoke Therapeutics's net income of -$10.5M. Notably, Arvinas's price-to-earnings ratio is -- while Stoke Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arvinas is 1.79x versus 8.75x for Stoke Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Zymeworks has a net margin of -76.18% compared to Arvinas's net margin of -75.75%. Arvinas's return on equity of -32.96% beat Zymeworks's return on equity of -30.45%.

Arvinas has a consensus price target of $41.74, signalling upside risk potential of 536.23%. On the other hand Zymeworks has an analysts' consensus of $21.35 which suggests that it could grow by 94.98%. Given that Arvinas has higher upside potential than Zymeworks, analysts believe Arvinas is more attractive than Zymeworks.

Arvinas has a beta of 2.305, which suggesting that the stock is 130.541% more volatile than S&P 500. In comparison Zymeworks has a beta of 1.176, suggesting its more volatile than the S&P 500 by 17.59%.

Arvinas has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zymeworks offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arvinas pays -- of its earnings as a dividend. Zymeworks pays out -- of its earnings as a dividend.

Arvinas quarterly revenues are $59.2M, which are larger than Zymeworks quarterly revenues of $31M. Arvinas's net income of -$45.1M is lower than Zymeworks's net income of -$23.5M. Notably, Arvinas's price-to-earnings ratio is -- while Zymeworks's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arvinas is 1.79x versus 10.89x for Zymeworks. Usually stocks with elevated PS ratios are considered overvalued.